tesaglitazar has been researched along with Innate Inflammatory Response in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Camejo, G; Havekes, LM; Jukema, JW; Lundholm, E; Princen, HM; Rensen, PC; van der Hoorn, JW | 1 |
Andersson, U; Berg, AL; Bjurström, S; Blomgren, B; Glinghammar, B; Hellmold, H; Skånberg, I; Stockling, K; Westerberg, R | 1 |
Boesten, LS; Camejo, G; Emeis, JJ; Havekes, LM; Jukema, JW; Kooistra, T; Lundholm, E; van Vlijmen, BJ; Zadelaar, AS | 1 |
3 other study(ies) available for tesaglitazar and Innate Inflammatory Response
Article | Year |
---|---|
The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
Topics: Alkanesulfonates; Animals; Aortic Valve; Apolipoprotein E3; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, VLDL; Female; Humans; Inflammation; Mice; Mice, Transgenic; Mutation; Phenylpropionates; PPAR alpha; PPAR gamma | 2009 |
Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.
Topics: Adipocytes; Adipose Tissue; Alkanesulfonates; Analysis of Variance; Animals; Biomarkers; Cell Proliferation; Fibrosarcoma; Gene Expression; Inflammation; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger | 2011 |
Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Topics: Alkanesulfonates; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Vessels; Cell Adhesion; Cholesterol; Cholesterol, Dietary; Collagen; Dietary Fats; Female; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Monocytes; NF-kappa B; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |